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Abstract
Background: HIV-1 subtype D infections, which are associated with a faster rate of progression and lymphocyte CD4
decline, cognitive deficit and higher mortality, have rarely been found in native Europeans. In Northwestern Poland,
however, infections with this subtype had been identified. This study aimed to analyze the sequence and clinical data for
patients with subtype D using molecular phylogeography and identify transmission clusters and ancestry, as well as drug
resistance, baseline HIV tropism and antiretroviral treatment efficacy.
Methods: Phylogenetic analyses of local HIV-1 subtype D sequences were performed, with time to the most recent common
ancestor inferred using Bayesian modeling. Sequence and drug resistance data were linked with the clinical and
epidemiological information.
Results: Subtype D was found in 24 non-immigrant Caucasian, heterosexually infected patients (75% of females, median
age at diagnosis of 49.5 years; IQR: 29–56 years). Partial pol sequences clustered monophyletically with the clades of
Ugandan origin and no evidence of transmission from other European countries was found. Time to the most common
recent ancestor was 1989.24 (95% HPD: 1968.83–1994.46). Baseline drug resistance to nucleoside reverse transcriptase
inhibitors was observed in 54.5% of cases (mutations: M41L, K103N, T215S/D) with evidence of clustering, no baseline
integrase or protease resistance and infrequent non-R5 tropism (13.6%). Virologic failure was observed in 60% of cases and
was associated with poor adherence (p,0.001) and subsequent development of drug resistance (p=0.008, OR: 20 (95%CI:
1.7–290).
Conclusions: Local subtype D represented an independently transmitted network with probably single index case, high
frequency of primary drug resistance and evidence of transmission clusters.
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Introduction
Phylogenetic analyses have been widely implemented in
molecular epidemiology of HIV infection and allowed not only
to understand genetic sequence variability, but also to trace the
flow of the variants and drug resistant clades as well as to infer a
rate of molecular evolution to date the ancestry [1]. Clusters of
sexual transmissions have been reconstructed and dated using
sequence data obtained for drug resistance genotyping, providing
information on the transmission patterns and allowing to identify
distinct epidemiological entities [2]. Tracking changes in HIV
epidemics related to subtype diversity and drug resistance is
important in Europe, where genetic diversity of HIV is rising, with
a trend to increase the prevalence of non-subtype B infections [3].
This variation is related either to immigration or the founder effect
with subsequent rapid spread within the populations at risk.
Migration from Africa and South America has been identified as a
major source of diversity in Western Europe [4] with multiple,
continuous inflow of the new clades into the population and
common association with heterosexual transmissions [5,6,7].
Onward infections with the non-subtype B clades reported in
Europe were mostly acquired from the partners originating from
countries of the higher HIV prevalence [8,9], however unique
epidemics among drug users have also been noted [10]. Such
explosive outbreaks in countries where drug injection is, or used to
be common, were observed both for subtype B and non-B clades.
This often results in high prevalence of a variant uncommon
elsewhere, as was the case in Estonia and Kaliningrad region of
Russia [11,12]. Studies have also revealed a nosocomial epidemics
with subtype F, of the Angolan ancestry, among children in
Romania due to a distribution of contaminated needles and blood
products [13,14].
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prevalence of minor drug resistance mutations in untreated
individuals and changes in virus tropism [15,16,17,18]. Prevalence
of major protease and reverse transcriptase mutations is similar
across the variants, however both virologic and immunologic
treatment efficacy is similar to the subtype B [19,20]. In general,
frequency of primary drug resistance differs locally in Europe,
often being associated with transmission clusters, fluctuates over
time and is usually limited to a single class of antiretrovirals
[21,22,23,24]. In Poland the prevalence of transmitted drug
resistance in the years 2006–2009 ranged from 3.9% to 7.4% [25].
The predominant subtype B was observed in 95.8% of the newly
diagnosed HIV infections [25].Of note, sexual transmissions now
tend to be the most common in Poland, which is a significant
change of epidemiological pattern from the earlier dominant
injection drug use related transmissions [26]. We have previously
identified higher prevalence of non-B subtypes, with a number of
subtype D clades in the local population from Northwestern
Poland (21%). These variants have been associated with more
advanced HIV disease and more common heterosexual transmis-
sion route if compared to the subtype B [27].
In this study the sequences and clinical data from a cluster of
locally diagnosed individuals infected with subtype D were
analyzed. Firstly, we used molecular phylogeography to trace the
import of subtype D into Poland, infer between-host phylogenies,
indentify transmission clusters and determine ancestry with
molecular clock methods. Secondly, baseline drug susceptibility
(protease, reverse transcriptase and integrase) and V3 based
predicted viral tropism were assessed. Finally, treatment efficacy
among patients infected with this variant and secondary drug
resistance were summarized.
Results
Group characteristics
Of the total of 190 patient sequences sampled so far in at the
Department of Infectious Diseases and Hepatology, Szczecin,
Poland HIV-1 subtype D was found in 24 (12.63%) cases. The first
case of the infection with this variant was confirmed in a year 1994
in a young female, who had never travelled outside Poland. All
cases were of Caucasian origin with the predominance of females
(n=18, 75%) and a median age at diagnosis of 49.5 years (IQR:
29–56 years). For only one patient presumed infection from a
partner travelling overseas (sailor) was recorded, however the
source sample was not available. Travel history for this contact is
not specific, with frequent worldwide travels and no clear African
connection. In the remaining cases no history of travel outside
Europe was noted.
For all cases heterosexual transmissions were recorded, and
patients were HCV antibody negative at HIV diagnosis. In one
case HCV infection with antibody production was observed in the
third year of observation. Patients tended to be diagnosed at
symptomatic stages of the HIV infection (n=21, 87.5%) with a
low baseline and nadir lymphocyte CD4 counts (median 62 cells/
ml [IQR: 23–246 cells/ml] and 35 cells/ml [IQR: 10–144 cells/ml,
respectively) and a high baseline HIV-1 viraemia (median of 5.6
log HIV-1 copies/ml [IQR: 4.9–6 log HIV-1 copies/ml]).
Total observation period in the group was 116 person-years
with a mean observation time of 57.82 months (95% CI: 35.37–
80.27). In fourteen cases (58.3%) AIDS was diagnosed within the
period of observation. Mortality rate was 3.44 per 100 person-
years. Of the four deaths recorded, three were AIDS-related and
occurred within the first year of observation; two cases of large
B-cell lymphoma, one Pneumocystis jirovecii pneumonia and the
fourth related to the cardiac event eight years after HIV
diagnosis.
Phylogeography and dated phylogeny of local subtype D
For the phylogeographic and dated phylogeny the earliest
possible sample from every patient was selected and sequenced.
The majority of samples were obtained from treatment-naive
patients (n=22, 91.7%), the remaining two samples were from
patients on ARV.
In the maximum likelihood tree all sequences from Poland
formed a monophyletic cluster nested within the Ugandan
sequences (figure 1, shown in red). Of note, subtype D sequences
found in various European countries (figure 1, marked in yellow)
were interspersed among various lineages of African origin, with
no clustering with Polish sequences. Branch lengths of our
sequences indicated independent evolution of the imported variant
without admixture of African variants or transmission to other
European countries.
In the reconstruction of the subtype D phylogeny, the
maximum likelihood tree (figure 2a) and the Bayesian clade
credibility tree (figure 2b) with dated ancestry had a similar
topology. Time to the most recent common ancestor inferred
using the relaxed clock model with GTR+c+C was in accordance
to the transmission dates from the patients’ documentation. Four
transmission sub-clusters may be observed with both maximum
likelihood bootstrap values and Bayesian posterior probability
.90% (figure 2b, sub-clusters numbered 1–4, blue boxes). Using
Bayesian Monte Carlo Markov Chain, dating to the time to the
most recent common ancestor (tMRCA) for all regional sequences
was the year 1989 (table 1). By the year 1994, which was the date
of the first confirmed infection with the subtype D, the virus was
probably already circulating locally. Bayesian skyline plot (figure 3)
indicated that a population size has been fairly stable over time
with a plateau in the last three years.
Clusters of drug resistance
Four observed clustered sequences were linked epidemiologi-
cally, which was reflected in the patients’ records – cases within the
sub-clusters 1–3 were sexual partners. Baseline drug resistance was
observed in 12 of the 22 antiretroviral naive patients (54.5%) with
pretreatment genotyping available. Primary drug resistance was
the most common within the fourth, the youngest (tMRCA in the
2002 [95% HPD: 2005.36–1998.52]) sub-cluster (10/11 cases,
90.9%), with nucleoside reverse transcriptase (NRTI) mutations
observed. Ten patients within this sub-cluster were female and one
male; epidemiological data from patients’ records suggested
possible sexual contacts between the man and at least three
women. Median age in this subgroup was 56 years (IQR: 53–60
years); all patients were diagnosed with clinical features of
immunodeficiency (category B and C according to the CDC
1993).
In two patients non-nucleoside reverse transcriptase (NNRTI)
drug resistant virus was observed in pretreatment samples (as
shown in figure 2b). It was possible to identify the source of
infection for one of these cases (sub-cluster 3, source marked with
asterisk, data from the sequencing of the sample taken after
virological failure, sequence not included in the tree). Frequency of
the baseline drug resistance has been shown in figure 4. No
baseline integrase or protease resistance was observed in the entire
group. Non-R5 tropism was assigned in three (13.6%) baseline,
treatment-naive samples with geno2pheno false positive rate (FPR)
threshold set to 10% (one if FPR of 5.75% was used), sequences
with FPR,10% were not clustered.
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resistance
The group of 20 (83.3%) patients were commenced on stable
antiretroviral therapy. Of the remaining one patient refused
consistently, one was lost to follow-up within a month following
the HIV diagnosis, one died before the treatment was introduced
and one died within the first month of treatment. The median for
the highest recorded lymphocyte CD4 count on cART was 369.5
(IQR: 294.25–596.5) cells/ml, with only five (25%) patients
maintaining stable CD4 count .500 cells/ml for at least six
months during the follow-up period. In 10 (50%) cases clinician
recorded poor adherence, while pharmacy records confirmed
,90% adherence in 9 (45%) patients. In 12 (60%) cases the
primary therapy was virologically successful (table 2), and as
expected, failure was associated with poor or ,90% adherence
(p,0.001) and development of drug resistance (p=0.008, OR: 20
(95%CI: 1.7–290). Secondary drug resistance was noted in all
eight failing patients with NRTI (M184V, T215 complex) and
NNRTI (K103N) being the most common mutations (figure 5). No
secondary protease drug resistance mutations were found in the
group. For virologically failing patients non-R5 tropism was
assigned in two of these cases (25%, geno2pheno algorithm with
FPR 10%); if FPR 5.75% was used the non-R5 tropism would be
called in one (12.5%) patient.
Interestingly, the treated patients with the baseline drug
resistance tended to present with higher rates of virologic success
if compared to the ones with drug susceptible viruses (90%, versus
30%, p=0.02997, 2-sided Fisher’s exact test), however this
phenomenon was associated with higher adherence.
Discussion
In this study we have evaluated the subtype D infections
occurring among Caucasian individuals from Northwestern
Poland. Differently to the cases of infection with this subtype
observed across Europe [15,17,28,29], the variant was found
among native, non-immigrant and non-travelling Poles, and
acquired locally. As is common in our country, HIV was
diagnosed late, usually with symptoms of immunodeficiency and
low baseline lymphocyte CD4 count [30]. Moreover, subtype D
diagnosis in the advanced stages of the disease may be related to a
faster clinical progression observed among patients infected with
this subtype, lower lymphocyte CD4 count during follow-up and
Figure 1. Relationships between the subtype D sequences inferred using maximum likelihood phylogeny (GenBank deposited pol
sequences). Country-specific sequences are marked with the same color: red – Poland, blue – Uganda, green – Tanzania, yellow – Europe (except
Poland), brown – Cameroon, magenta - Senegal, cyan- Sudan, dark green – other African countries, violet – South America, grey – Asia, orange –
North America.
doi:10.1371/journal.pone.0031674.g001
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[31,32,33]. This may be the result of the increased degree of
apoptosis in lymphocyte CD4 populations prior to the start of the
antiretroviral treatment and a higher number of inhibitory
programmed cell death receptors on the CD4 cells [34]. Mortality
in the group was slightly higher if compared to the entire cohort
(majority infected with the subtype B) from the region (3.44 versus
2.66 deaths per 100 person-years), which is in accordance to the
previous reports [25,35,36,37,38]. Of note, all infections were
associated with heterosexual transmissions with a percentage of
infected women and mean age at diagnosis higher than among
typical HIV positive population observed in Poland (75% versus
24.4%, respectively [26]). This may partially explain late diagnosis
and as a consequence higher mortality and lower lymphocyte CD4
counts as heterosexual females, especially in peri- and postmen-
opausal period, are infrequently tested for HIV.
Observed infections with subtype D infections formed a network
with probably one index case and subsequent local spread. This
cluster of heterosexually acquired infections seemed independent
from subtype B ones spreading among men who have sex with
men (MSM),injection drug users (IDU) and heterosexual popula-
tions [27]. Dated phylogeny and phylogeographic analyses
suggested that the tMRCA of the subtype D found in Poland is
1989.2 (95% HPD: 1994.46–1968.83) and is of Ugandan origin.
The sequences cluster monophyletically within the sequences from
Uganda, which confirmed a single transmission event in the past
with the subsequent local spread. Local character of the
transmissions was further confirmed by a lack of clustering with
sequences from other European countries. Networks of transmis-
sion had been investigated both for B and non-B subtype infections
using Bayesian MCMC inference methods, with identification of
transmission clusters among MSM [2,39] and heterosexual
individuals [40]. Despite evidence of the slower dynamics among
heterosexually acquired non-B subtypes, both small and large
clusters with epidemiologically linked patients were found in the
studies cited above. Similarly, in our study three small (two
sequences) and one large (eleven) clusters were identified.
Moreover, the Bayesian skyline plot indicates a stable population
size. Dated phylogeny for the large cluster revealed that the
majority of these transmissions occurred within the short period of
time, probably in the early stage of infection.
Additionally, the high frequency of primary drug resistance
mutations (DRMs) observed in this study was associated to the
observed clustering within the network of transmission and
presence of M41L and T215 revertant mutations. Similar results
were reported in various countries for different subtypes, with most
common transmission of NRTI DRMs [22,41,42,43]. As expect-
ed, no integrase inhibitor (InI) transmitted resistance was found,
which is consistent to the fact that all infections were acquired
before introduction of InI in the clinical practice. We noted, that
Figure 2. Phylogenetic trees of the subtype D sequences from Northwestern Poland. Figure a - maximum likelihood tree with bootstrap
values for 1000 replicates drawn at the branches. Figure b – time scaled Bayesian MCMC tree. On the tree branches estimated time to the most recent
common ancestor (tMRCA) and posterior probabilities expressed as percentage are shown. For both figures clustered sequences are marked in red
and four identified clusters indicated as blue boxes and numbered are drawn on the right. Drug resistance mutations are marked at the tip nodes
after the sequence identifier. *source patient for the transmission of the drug resistance within the cluster.
doi:10.1371/journal.pone.0031674.g002
Table 1. Time to the most recent common ancestors (tMRCA) for the entire cluster and sub-clustered sequences.
tMRCA (years) 95% HPD (value) 95% HPD (years, calibrated to the youngest tip)
All sequences 1989.24 16.85–42.48 1994.46–1968.83
cluster 1 2001.43 6.38–11.98 2004.93–1999.33
cluster 2 1999.05 10.38–19.16 2000.93–1992.15
cluster 3 1996.79 13.39–17.15 1997.92–1994.16
cluster 4 2002.76 5.95–12.79 2005.36–1998.52
doi:10.1371/journal.pone.0031674.t001
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individuals newly diagnosed, treatment-naive patients (cluster 4)
and from a chronically infected, heavily treated patient (cluster 3).
Both phenomena have been described previously [43,44,45,
46,47], however this has been the first report on clustered drug
resistance in Caucasians with subtype D. Non-R5 viruses were
found infrequently in the group (in 13.6% when FPR 10% was
used for the tropism assignment and 4.5% for 5.75 FPR), similarly
to the result (14.8%) from a phenotypic assay performed in French
patients [48]. Of note, our finding is in contrast to the studies
demonstrating a high frequency of an 64 tropism in Ugandan
clades [49].
Immunologic and virologic antiretroviral therapy efficacy in the
observed, stably treated group was poorer than expected for
individuals on cART with no specific drug combination clearly
superior in the group. Virologic failure was noted in 40% of cases,
compared to the 24.7% in the European observational studies
[50]. Association between poor adherence, treatment failure and
development of secondary drug resistance was obvious, however
the fact that the primary drug resistance did not affect the virologic
treatment efficacy in the setting of good adherence must be
acknowledged. It may be hypothesized that the poor adherence
may be associated with the higher probability of cognitive
impairment observed among individuals infected with this subtype
[51]. Recently a pathogenetic mechanism of this phenomenon was
proposed, as a certain features of the subtype D nef protein 3D
structure was associated with long-term progressive dementia in
HIV patients, suggesting that this cognitive deficit may be related
to the altered folding or binding potential of this protein [52].
It has to be noted, that the limitations of this study can be
related to the fact that the certain samples with subtype D might
have remained undetected, as it was not possible to sequence all
the samples from the patients followed-up in the centre. Neither
index case, nor the certain source patient for the cluster 4 were
found.
To sum up, local spread of HIV-1 subtype D infections
described here represented an independent cluster, detected
among heterosexually exposed individuals in parallel to the widely
distributed subtype B infections. In phylogenetic inference analyses
Ugandan origin of the virus was identified with probable single
transmission event. Frequency of drug resistance in this group was
high, especially within sub-clustered sequences, while the treat-
ment efficacy was poor and independent of the primary drug
resistance. Late diagnoses and association with heterosexual mode
of transmission might fuel spread of these infections, especially in
the light of evidence for the epidemiological clustering which
suggests that new transmissions of HIV subtype D have been
under diagnosed.
Methods
Population and ethics statement
For the study participants followed up at the Department of
Infectious Diseases and Hepatology, Szczecin, Poland were
Figure 4. Frequency of baseline drug resistance mutations
among treatment-naive patients.
doi:10.1371/journal.pone.0031674.g004
Figure 3. Bayesian skyline plot for estimation of the number of subtype D HIV-1 cases in the local population. 95% CI are marked in
blue. Y-axis: predicted number of cases (log scale), X-axis: timescale (years).
doi:10.1371/journal.pone.0031674.g003
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mostly from the Northwest part of Poland from the early 90-ties,
and so far 960 patients have been observed. Clinical, epidemio-
logical and laboratory data have been collected as a part of a
routine patient care. The study has been approved by the local
ethical committee of Pomeranian Medical University, Szczecin,
Table 2. Drug resistance and treatment efficacy in the group infected with subtype D.
No
Patient
ID
Gender
(F- female,
M-male)
Year HIV
diagnosed
Transmitted
drug resistance
(RT codons)
Virologic
success of
the first
therapy
Adherence
(clinician
assigned)*
Secondary
drug resistance
(accumulated,
RT codon
position)
Virological
control
achieved on
1 20 F 1994 none no 46% (poor) L74V, K103N, L100I Never achieved
2 69 F 1996 Not available No 50% (poor) M184V, T215N,
T215S, T215Y,
K103N
NRTI+PI+InI
3 258 F 1997 none Treatment naive
4 467 F 2003 none yes 100% (adequate) None NRTI+PI
5 504 M 2003 none no 45,69% (poor) K103N NRTI+PI
6 508 F 2003 none yes 86,89% (medium) None NRTI+NNRTI
7 546 M 2004 Not available no 78,46% (poor) M184V NRTI+PI
8 558 M 2004 V179E Death before assessment
9 559 F 2004 none no 19,98% (poor) M184V Never achieved
10 562 F 2004 none yes 62,11% (poor) None NRTI+NNRTI
11 643 M 2006 none no 81,76% (poor) K65R, K70E,
M184V, V106A,
F227L
NRTI+NNRTI, PIs+NNRTI,
NRTI+PI
12 645 F 2006 none no 89,49 (poor) K103N, P225H,
F227L, M184I
NRTI+NNRTI, NRTI+FI+PI
13 711 F 2007 M41L, T215S yes 99,35% (adequate) None NRTI+PI
14 743 F 2008 M41L yes 97,44% (adequate) None NRTI+NNRTI, NRTI+PI,
NRTI+InI
15 744 F 2008 M41L, T215S yes 97,33% (adequate) None NRTI+PI
16 766 F 2008 T215D yes 96,45% (adequate) None NRTI+NNRTI, NRTI+InI
17 781 M 2008 M41L, T215S yes 93,53% (adequate) None NRTI+NNRTI
18 787 M 2008 K103N Treatment naive, lost to follow-up
19 837 F 2009 M41L, T215S yes 100,00% (adequate) None NRTI+PI
20 894 F 2010 M41L, T215D yes 94,49% (adequate) None NRTI+PI, NRTI+InI
21 911 F 2010 M41L, T215S yes 98,55% (adequate) None NRTI+InI
22 931 F 2011 M41L, T215D Yes 100,00% (adequate) None NRTI+InI
23 934 F 2011 none no 94,29% (poor) M184I, Y181C NRTI+PI
24 KT F 2009 T215S Treatment naive, death before assessment
*Percentage expressed adherence based on the number of months of medications dispensed by the number of months of follow-up; clinician assigned adherence
based on the patient’s statement regarding missed doses and treatment interruptions.
doi:10.1371/journal.pone.0031674.t002
Figure 5. Frequency of secondary drug resistance mutations in patients failing antiretroviral therapy.
doi:10.1371/journal.pone.0031674.g005
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available have been analyzed. Treatment adherence was assessed
based on the patient records (number of months of medications
dispensed by the number of months of follow-up, expressed as a
percentage) as well as clinical assessment based on the patient’s
statement regarding missed doses at home or treatment interrup-
tions. Antiretroviral therapy was commenced according to the
clinical standard at the time of introduction, stable therapy was
defined as .30 consecutive days of uninterrupted treatment.
Virologic success of the therapy was defined as stable serum viral
load ,400 copies/ml in the first available analysis following 6
months of treatment, and as a consequence no evidence of
secondary drug resistance.
Genotyping and subtyping
Plasma samples collected from patients between the years 1996
and 2011 were stored at 280 degrees C and analyzed
retrospectively. HIV RNA extraction as well as reverse transcrip-
tase and protease genotyping was performed using Viroseq 2.7
and 2.8 genotyping assays (Abbott Molecular, Abbott Park, IL)
according to manufacturer’s protocol. Initial subtyping was
performed using REGA genotyping 2.0 tool (http://bioafrica.
mrc.ac.za/rega-genotype/html/subtypinghiv.html) based on the
partial pol sequence obtained by Viroseq methodology. Obtained
protease/reverse transcriptase sequences were 1302 b.p. long;
location from the start of HXB2 genome: positions 2253–3525.
Subsequently, the subtype was confirmed in phylogenetic analysis
with a selection of reference sequences listed in the HIV Sequence
Compendium 2010 (Los Alamos National Laboratory, Los
Alamos, U.S.A. http://www.hiv.lanl.gov). For this purpose
bootstrapped (1000 replicates) neighbor-joining tree with Kimura
2 parameter model was used (MEGA version 4.0 [53]). To exclude
recombinant sequences, bootscanning (200 base pair (b.p.)
window, step 20 b.p., Kimura 2 parameter model) using Simplot
software (S. Ray, John Hopkins University, Baltimore, USA) with
a set of reference sequences was performed [54]. When necessary,
samples from treatment-failing subtype D patients (genotyped for
the purpose of drug resistance monitoring) were resequenced from
the baseline (first available) sample. V3 sequences were obtained
from both baseline and on-treatment samples while integrase was
sequenced from the first samples only. HIV-1 integrase was
amplified and sequenced using reagents and conditions specified
by Laethem et al. [55], with the following amplification and
sequencing primers: AGGAGCAGAAACTTWCTATGTAGAT-
GG (outer forward), TTCTTCCTGCCATAGGARATGCCTA-
AG (outer reverse), TTCRGGATYAGAAGTAAAYATAGTAA-
CAG (inner forward), TCCTGTATGCARACCCCAATATG
(inner reverse and sequencing reverse), GCACAYAAAGGRA-
TTGGAGGAAATGAAC (sequencing, forward), GGVATTCC-
CTACAATCCCCAAAG (sequencing, forward), GAATACTGC-
CATTTGTACTGCTG (sequencing, reverse). Obtained integrase
sequences were 866 b.p. long, location from the start of HXB2
genome: positions 4230–5096. V3 loop sequencing was carried out
following the protocol provided by the HIV Centre of Excellence
(personal communication, prof. Richard Harrigan), with the
following amplification and sequencing primers: GAGCCAA-
TTCCCATACATTATTGT (outer forward), GCCCATAGT-
GCTTCCTGCTGCTCCCAAGAACC (outer reverse), TGTG-
CCCCAGCTGGTTTTGCGAT (inner forward), TATAATTC-
ACTTCTCCAATTGTCC (inner reverse), AATGTCAGYACA-
GTACAATGTACAC (sequencing, forward), GAAAAATTC-
CCTTCCACAATTAAA (sequencing, reverse). Obtained inte-
grase sequences were 107 b.p. long, location from the start of
HXB2 genome: positions 7110–7217. Briefly, nested PCR was
carried out following reverse transcription of extracted HIV-1
RNA as stated in the methodologies cited above. Amplicons were
used for sequencing by standard techniques with BigDye
technology using an ABI 3500 platform (Applied Biosystems,
Foster City, CA, USA). V3 loop analyses were done in triplicate.
Two overlapping sequencing reactions (forward and reverse) were
performed for each sample. Reverse transcriptase and protease
sequences were assembled with a software provided with a Viroseq
2.8 kit, while V3 and integrase sequences using the Recall online
tool (http://pssm.cfenet.ubc.ca) [56]. Integrase and V3 sequences
were obtained for all patients. Obtained V3 sequence data were
interpreted using the geno2pheno tool (www.geno2pheno.org)
with two FPR thresholds: 10% (as suggested by the European
Guidelines on HIV Tropism testing) and 5.75% (from the Merit
trial) [57,58,59].Drug resistance interpretation was performed
using the Stanford DB database (hivdb.stanford.edu) [60] with
transmitted HIV-1 drug resistance interpreted according to the
surveillance recommendations [61,62].
Phylogenetic inference
To analyze the origin of our sequences, we have downloaded all
HIV-1 group M subtype D pol sequences of at least 900 b.p.
length, stored in the GenBank, using Los Alamos National
Laboratory HIV sequence database (www.hiv.lanl.gov accessed on
16.09.2011). This dataset of 741 sequences was aligned with our
partial pol sequences using Clustal 62.0.10 (www.clustal.org).
Bootstrapped (1000 replicates) maximum likelihood phylogeny
using a GTR+c model with empirical nucleotide frequencies was
inferred using PAUP* v. 4.0 (http://paup.csit.fsu.edu/order.html).
Separate analyses were performed for the dataset of 24 local
sequences with maximum-likelihood methodology (bootstrapped
with 1000 replicates) using PHYML v. 3.0 software with subtree
pruning and regrafting (SPR) algorithm under GTR substitution
model [63]. Moreover, to estimate the time to the most recent
common ancestor (tMRCA) for local sequences we used a
Bayesian Monte Carlo Marcov Chain (MCMC). Two replicates
of 10 million generations were run in BEAST v. 1.5.3 [64], under
the scenarios of the constant and exponential population size as
well as Bayesian skyline plot using a GTR+c+C and HKY models
with uncorrelated lognormal relaxed molecular clock [1]. Log
likelihoods for the models presented were as follows: 25790.27 for
the relaxed a GTR+c+C model with constant population size,
25790.27 for the relaxed a GTR+c+C model with an exponential
prior, 25833.38 for relaxed a GTR+2 codon positions with
constant population size, 25837.73 for the HKY model. Models
were compared using Chi-square distribution test, allowing to
identify that GTR+2 codon position and HKY models were
significantly less fit than the GTR+c+C. As a GTR+c+C models
with constant population size and exponential priors were not
statistically different, we have selected the scenario with the lowest
marginal likelihood (constant population size). A consensus tree
with posterior probabilities for branch support was obtained and
annotated with TreeAnnotator v. 1.5.4. All trees were visualized in
Figtree v.1.2.2.
Statistics
Statistical comparisons were performed using the Fisher’s exact
t tests for nominal variables while continuous variables were
analyzed using the U-Mann Whitney test using Statistica 8.0 PL
software (Statasoft, Poland).
Sequence data
HIV-1 subtype D sequences from this study sequences were
submitted to the GenBank and may be accessed with the following
HIV-1 Subtype D from Northwestern Poland
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GU906874, JQ305750–JQ305792.
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